Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity

Sidharth S. Bhardwaj, Naga Chalasani

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.

Original languageEnglish
Pages (from-to)597-613
Number of pages17
JournalClinics in Liver Disease
Volume11
Issue number3
DOIs
StatePublished - Aug 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Liver Diseases
Hyperlipidemias
Lipids
Chronic Disease
Pharmaceutical Preparations
Liver
Expert Testimony
Fatty Liver
Biochemistry
Fibrosis
Non-alcoholic Fatty Liver Disease

ASJC Scopus subject areas

  • Hepatology

Cite this

Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity. / Bhardwaj, Sidharth S.; Chalasani, Naga.

In: Clinics in Liver Disease, Vol. 11, No. 3, 08.2007, p. 597-613.

Research output: Contribution to journalArticle

Bhardwaj, Sidharth S. ; Chalasani, Naga. / Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity. In: Clinics in Liver Disease. 2007 ; Vol. 11, No. 3. pp. 597-613.
@article{c60be1fa0b01498eb84e1cd62f538c79,
title = "Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity",
abstract = "The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.",
author = "Bhardwaj, {Sidharth S.} and Naga Chalasani",
year = "2007",
month = "8",
doi = "10.1016/j.cld.2007.06.010",
language = "English",
volume = "11",
pages = "597--613",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity

AU - Bhardwaj, Sidharth S.

AU - Chalasani, Naga

PY - 2007/8

Y1 - 2007/8

N2 - The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.

AB - The effort to reduce cardiovascular risk factors, including hyperlipidemia, has led to the increased use of lipid-lowering agents. Hyperlipidemic patients often have underlying fatty liver disease, however, and thus may have elevated and fluctuating liver biochemistries. Therefore, caution should be applied before attributing elevated liver tests to lipid-lowering agents. Data indicate that patients who have chronic liver disease and compensated cirrhosis should not be precluded from receiving statins to treat hyperlipidemia. Several recent studies and expert opinion currently fully endorse statin use in patients who have nonalcoholic fatty liver disease and other chronic liver disease if clinically indicated.

UR - http://www.scopus.com/inward/record.url?scp=34548190309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548190309&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2007.06.010

DO - 10.1016/j.cld.2007.06.010

M3 - Article

VL - 11

SP - 597

EP - 613

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 3

ER -